Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 2/20 | 0.50 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179154 | 0.88 | F10 (0.50) | RAB9ANPC1F10DEGS1MAPT | |
| SCHEMBL890791 | 0.87 | F10 (0.57) | RAB9ANPC1MITFF10DEGS1 | |
| SCHEMBL890890 | 0.86 | RAB9A (0.51) | RAB9ANPC1MITFF10DEGS1 | |
| SCHEMBL890808 | 0.85 | RAB9A (0.54) | RAB9ANPC1MITFF10MAPT | |
| SCHEMBL16362002 | 0.84 | KDM4E (0.43) | DEGS1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL10178447 | 0.83 | F10 (0.61) | F10 | |
| SCHEMBL890820 | 0.82 | F10 (0.64) | F10KDM4EALDH1A1HPGD | |
| SCHEMBL890722 | 0.82 | F10 (0.54) | RAB9ANPC1F10DEGS1KMT2A | |
| SCHEMBL890777 | 0.81 | F10 (0.62) | RAB9ANPC1F10DEGS1KMT2A | |
| SCHEMBL10177896 | 0.78 | F10 (0.64) | RAB9ANPC1MITFF10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4744050-B2 | Benzamides And Related Inhibitors Of Factor Xa | — | 2011-08-10 | — | — | JP | claimed |
| EP-1216228-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001019788-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20060020039-A1 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | US | disclosed |
| US-6835739-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040097561-A1 | For therapy of thrombosis | MILLENNIUM PHARMACEUTICALS, INC. | 2004-05-20 | — | — | US | disclosed |
| US-20030162690-A1 | Bood anticoagulant | COR THERAPEUTICS, INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1259485-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6376515-B2 | DERIVATIVES OF A 2-((4-AMIDINYLPHENYL)-CARBONYLAMINO-1,2-PHENYLENE)-CARBONYLAMINO-) PYRIDINE; POTENT AND HIGHLY SELECTIVE ANTICOAGULANTS; BIOAVAILABILITY AND/OR SOLUBILITY; PREVENTION AND TREATMENT OF THROMBOSIS AND COAGULATION | COR THERAPEUTICS, INC. | 2002-04-23 | — | — | US | disclosed |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001064642-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064643-A2 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020039-A1 | Benzamides and related inhibitors of factor Xa | TFPI, F12, F11 | RAB9A 2552/4885NPC1 2990/4885MITF 1418/4885 |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | RAB9A 2674/4885NPC1 2184/4885MITF 1179/4885 |
| US-20040097561-A1 | For therapy of thrombosis | F2, F12, TFPI | RAB9A 3004/4885NPC1 2691/4885MITF 3388/4885 |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | RAB9A 2674/4885NPC1 2184/4885MITF 1179/4885 |
| US-20020002183-A1 | Derivatives of a 2-((4-amidinylphenyl)-carbonylamino-1,2-phenylene)-carbonylamino-)pyridine; potent and highly selective anticoagulants; bioavailability and/or solubility; prevention and treatment of thrombosis and coagulation | F2, F12, PLAT | RAB9A 3299/4885NPC1 2797/4885MITF 3602/4885 |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | TFPI, F12, TFPI2 | RAB9A 2674/4885NPC1 2184/4885MITF 1179/4885 |
| US-20030162690-A1 | Bood anticoagulant | F2, SERPINC1, HABP2 | RAB9A 1551/4885NPC1 1829/4885MITF 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.